Veracyte, Inc. (VCYT) stock
VCYTNasdaqServices-Medical LaboratoriesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/3029% below fair value
$25.57+1.34 (+5.53%)
Close on Nov 18, 2026Market cap $2.06BP/E 18.3Yield –
Veracyte revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Veracyte's revenue for the twelve months ending Jun 30, 2026 was $561.90M, up 17.3% year over year. For fiscal 2025 it was $517.15M, up 16.0% from the year before. Over ten years it grew 26.4% a year on average. The highest annual figure on record is $517.15M in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $517.15M | +16.0% |
| FY2024 | Dec 31, 2024 | $445.76M | +23.5% |
| FY2023 | Dec 31, 2023 | $361.05M | +21.8% |
| FY2022 | Dec 31, 2022 | $296.54M | +35.1% |
| FY2021 | Dec 31, 2021 | $219.51M | +86.8% |
| FY2020 | Dec 31, 2020 | $117.48M | -2.4% |
| FY2019 | Dec 31, 2019 | $120.37M | +30.8% |
| FY2018 | Dec 31, 2018 | $92.01M | +27.9% |
| FY2017 | Dec 31, 2017 | $71.95M | +10.6% |
| FY2016 | Dec 31, 2016 | $65.09M | +31.5% |
| FY2015 | Dec 31, 2015 | $49.50M | +29.6% |
| FY2014 | Dec 31, 2014 | $38.19M | +74.5% |
| FY2013 | Dec 31, 2013 | $21.88M | +88.2% |
| FY2012 | Dec 31, 2012 | $11.63M | +339.6% |
| FY2011 | Dec 31, 2011 | $2.65M | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $150.32M | +15.5% |
| Q1 FY2026 | Mar 31, 2026 | $139.07M | +21.5% |
| Q4 FY2025 | Dec 31, 2025 | $140.64M | +18.5% |
| Q3 FY2025 | Sep 30, 2025 | $131.87M | +13.8% |
| Q2 FY2025 | Jun 30, 2025 | $130.16M | +13.8% |
| Q1 FY2025 | Mar 31, 2025 | $114.47M | +18.2% |
| Q4 FY2024 | Dec 31, 2024 | $118.63M | +20.8% |
| Q3 FY2024 | Sep 30, 2024 | $115.86M | +28.6% |
| Q2 FY2024 | Jun 30, 2024 | $114.43M | +26.7% |
| Q1 FY2024 | Mar 31, 2024 | $96.84M | +17.5% |
| Q4 FY2023 | Dec 31, 2023 | $98.20M | +22.3% |
| Q3 FY2023 | Sep 30, 2023 | $90.11M | +19.2% |
| Q2 FY2023 | Jun 30, 2023 | $90.32M | +24.0% |
| Q1 FY2023 | Mar 31, 2023 | $82.42M | +21.6% |
| Q4 FY2022 | Dec 31, 2022 | $80.30M | +19.2% |
| Q3 FY2022 | Sep 30, 2022 | $75.59M | +25.2% |
| Q2 FY2022 | Jun 30, 2022 | $72.86M | +32.2% |
| Q1 FY2022 | Mar 31, 2022 | $67.78M | +84.7% |
| Q4 FY2021 | Dec 31, 2021 | $67.34M | +95.0% |
| Q3 FY2021 | Sep 30, 2021 | $60.37M | +94.0% |
| Q2 FY2021 | Jun 30, 2021 | $55.11M | +166.2% |
| Q1 FY2021 | Mar 31, 2021 | $36.70M | +17.9% |
| Q4 FY2020 | Dec 31, 2020 | $34.54M | +16.2% |
| Q3 FY2020 | Sep 30, 2020 | $31.12M | +0.5% |
| Q2 FY2020 | Jun 30, 2020 | $20.70M | -31.3% |
| Q1 FY2020 | Mar 31, 2020 | $31.12M | +5.4% |
| Q4 FY2019 | Dec 31, 2019 | $29.73M | +15.5% |
| Q3 FY2019 | Sep 30, 2019 | $30.97M | +32.0% |
| Q2 FY2019 | Jun 30, 2019 | $30.14M | +32.5% |
| Q1 FY2019 | Mar 31, 2019 | $29.53M | +47.3% |
| Q4 FY2018 | Dec 31, 2018 | $25.75M | +31.4% |
| Q3 FY2018 | Sep 30, 2018 | $23.47M | +33.9% |
| Q2 FY2018 | Jun 30, 2018 | $22.75M | +23.6% |
| Q1 FY2018 | Mar 31, 2018 | $20.04M | +22.0% |
| Q4 FY2017 | Dec 31, 2017 | $19.60M | +7.3% |
| Q3 FY2017 | Sep 30, 2017 | $17.52M | -5.8% |
| Q2 FY2017 | Jun 30, 2017 | $18.41M | – |
| Q1 FY2017 | Mar 31, 2017 | $16.43M | – |
| Q4 FY2016 | Dec 31, 2016 | $18.26M | – |
| Q3 FY2016 | Sep 30, 2016 | $18.60M | – |
See a number that looks wrong?